Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Imugene Limited

Market Cap 47.82M 33.53M 29.23M 27.07M 25.35M 47.53M 3.16B 321M 124M 1.56B 126M 123M 5.41B P/E 2026 *
-0.98x
P/E 2027 * -1.46x
Enterprise Value 47.52M 33.32M 29.05M 26.9M 25.19M 47.24M 3.14B 319M 124M 1.55B 125M 122M 5.37B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.9%
Yield 2026 *
-
Yield 2027 * -
1 day-4.35%
1 week+4.76%
Current month-4.35%
1 month-15.38%
3 months-21.43%
6 months-65.08%
Current year-69.86%
1 week 0.1
Extreme 0.095
0.12
1 month 0.09
Extreme 0.09
0.14
Current year 0.09
Extreme 0.09
0.41
1 year 0.09
Extreme 0.09
0.48
3 years 0.09
Extreme 0.09
5.1
5 years 0.09
Extreme 0.09
21.25
10 years 0.09
Extreme 0.09
21.25
Manager TitleAgeSince
Chief Executive Officer - 2016-10-31
Director of Finance/CFO - 2025-03-03
Chief Tech/Sci/R&D Officer - 2023-08-31
Director TitleAgeSince
Chairman 70 2012-10-30
Director/Board Member - 2018-03-27
Director/Board Member 66 2019-04-22
Date Insider Type Main position Quantity % Market Cap.
12-18Fiscal year

Director

14,706 0.0047%
12-18Free

Director

29,411 0.0093%
12-18Free

Founder

124,054 0.0393%
Change 5-day change 1-year change 3-year change Capi.($)
-4.35%+4.76%-75.11%-96.44% 33.53M
+0.74%+1.29%-10.62%-4.86% 43.13B
+3.31%+5.93%+310.97%+532.23% 34.65B
+2.84%+2.14%+9.34%+45.55% 30.03B
-1.70%-7.54%+8.43%-21.54% 28B
-1.90%-1.56%+10.24%+22.81% 24.45B
-0.14%+5.86% - - 14.34B
+0.68%-1.53%+48.76%+108.76% 13.14B
+0.35%-1.10%+5.31%+7.51% 12.53B
-0.26%+1.15%+98.13%+79.60% 12.25B
Average -0.37%+3.30%+45.05%+74.85% 21.26B
Weighted average by Cap. +0.16%+1.28%+65.54%+111.24%

Financials

2026 *2027 *
Net sales - -
Net income -56.97M -39.95M -34.83M -32.26M -30.2M -56.63M -3.77B -383M -148M -1.86B -150M -147M -6.44B -42.79M -30M -26.16M -24.22M -22.68M -42.53M -2.83B -287M -111M -1.39B -113M -110M -4.84B
Net Debt -300K -210K -183K -170K -159K -298K -19.85M -2.01M -781K -9.77M -790K -773K -33.92M -1M -701K -611K -566K -530K -994K -66.16M -6.72M -2.6M -32.56M -2.63M -2.58M -113M
Logo Imugene Limited
Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.
Employees
15
Date Price Change Volume
26-06-22 0.1100 $ -4.35% 1,523,443
26-06-19 0.1150 $ +21.05% 6,567,103
26-06-18 0.0950 $ -4.04% 1,513,135
26-06-17 0.0990 $ +1.02% 2,886,998
26-06-16 0.0980 $ -6.67% 2,150,500
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1150AUD
Average target price
0.3067AUD
Spread / Average Target
+166.67%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!